---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-25-000096"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:24:34.360402+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY

## Summary
- Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.
- TissueCypher test reports nearly doubled to 9,170 (from 4,782); DecisionDx-Melanoma up 4% to 9,981.
- Raising FY2025 total revenue guidance to $310-320M from $287-297M, citing strong core test performance.
- Net income $4.5M ($0.16 diluted EPS) vs $8.9M ($0.32) YoY; adjusted EBITDA $10.4M vs $21.5M.
- FDA Breakthrough Device designation for DecisionDx-Melanoma; closed Previse acquisition and SciBase collaboration.

## SEC filing metadata
- accession: 0001447362-25-000096
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736225000096/0001447362-25-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736225000096/cstl-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-25-000096
- JSON: https://secwatch.observer/filing/0001447362-25-000096.json
- Plain text: https://secwatch.observer/filing/0001447362-25-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.